Midkine促進黑色素瘤免疫耐受和免疫抵抗狀態的產生
作者:
小柯機器人發布時間:2020/10/20 15:54:31
西班牙國家癌症研究中心(CNIO) Mara S. Soengas和David Olmeda課題組合作取得一項新成果。他們發現Midkine重塑黑色素瘤微環境導致免疫耐受和免疫抵抗狀態的產生。2020年10月19日的《自然-醫學》發表了這項成果。
研究人員發現在炎性但免疫逃逸的微環境中,黑色素瘤分泌的驅動因子Midkine(MDK)預示了不良患者預後和對免疫檢查點阻滯的抵抗。從機制上講,MDK調控黑素瘤細胞的轉錄組,協同激活調控核因子-κB以及下調幹擾素相關途徑。MDK調控分泌蛋白組誘導巨噬細胞產生促進CD8+ T細胞功能障礙耐受的表型。相反,靶向MDK導致黑色素瘤細胞對抗PD-1 /抗PD-L1治療敏感。
這些發現強調了翻譯相關性,MDK缺失腫瘤的表達譜豐富了獨立患者隊列中對免疫檢查點阻滯療法反應的關鍵指標。總得來說,這些數據表明MDK充當自分泌和旁分泌信號的內部調節因子,可在侵襲性黑素瘤中維持免疫抑制。
據了解,在諸如黑色素瘤等侵襲性癌症中,一個懸而未決的問題是,惡性細胞如何重塑免疫系統使其發揮促癌功能。
附:英文原文
Title: Midkine rewires the melanoma microenvironment toward a tolerogenic and immune-resistant state
Author: Daniela Cerezo-Wallis, Marta Contreras-Alcalde, Kevin Troul, Xavier Catena, Cynthia Mucientes, Tonantzin G. Calvo, Estela Can, Cristina Tejedo, Paula C. Pennacchi, Sabrina Hogan, Peter Klblinger, Hctor Tejero, Andrew X. Chen, Nuria Ibarz, Osvaldo Graa-Castro, Lola Martinez, Javier Muoz, Pablo Ortiz-Romero, Jos L. Rodriguez-Peralto, Gonzalo Gmez-Lpez, Ftima Al-Shahrour, Ral Rabadn, Mitchell P. Levesque, David Olmeda, Mara S. Soengas
Issue&Volume: 2020-10-19
Abstract: An open question in aggressive cancers such as melanoma is how malignant cells can shift the immune system to pro-tumorigenic functions. Here we identify midkine (MDK) as a melanoma-secreted driver of an inflamed, but immune evasive, microenvironment that defines poor patient prognosis and resistance to immune checkpoint blockade. Mechanistically, MDK was found to control the transcriptome of melanoma cells, allowing for coordinated activation of nuclear factor-κB and downregulation of interferon-associated pathways. The resulting MDK-modulated secretome educated macrophages towards tolerant phenotypes that promoted CD8+ T cell dysfunction. In contrast, genetic targeting of MDK sensitized melanoma cells to anti-PD-1/anti-PD-L1 treatment. Emphasizing the translational relevance of these findings, the expression profile of MDK-depleted tumors was enriched in key indicators of a good response to immune checkpoint blockers in independent patient cohorts. Together, these data reveal that MDK acts as an internal modulator of autocrine and paracrine signals that maintain immune suppression in aggressive melanomas. Tumor-secreted midkine modulates immune tolerance in the melanoma tumor microenvironment and determines resistance to immune checkpoint blockade.
DOI: 10.1038/s41591-020-1073-3
Source: https://www.nature.com/articles/s41591-020-1073-3